The increasing MDR/XDR-TB problem poses a major threat to TB control, and HIV infection threatens to further aggravates the problem. Mycobacterial persistence underlies lengthy therapy and is often the root cause for drug resistance due to poor compliance to lengthy therapy, thus there is significant interest to develop novel drugs based on new mechanisms of drug resistance and persistence. WhiB7 is a transcription factor, which controls a region of 8 genes including tap (Rv1258c), encoding an efflux protein for tetracycline and aminoglycoside excretion, and plays a key role in the intrinsic antibiotic resistance and possibly tolerance or persistence. Treated chronic bacterial or fungal infections harbor variants with increased antibiotic tolerance associated with polymorphisms in toxin-antitoxin (TA) genes involved in persistence. Clinical isolates of M. tb harbor mutations in whiB7, tap and TA genes, but the role of these mutations in drug tolerance/persistence is unknown. Furthermore, a new mechanism of pyrazinamide (PZA) resistance due to mutations in drug target RpsA involved in trans-translation was recently identified, but the role of rpsA mutations in contributing to PZA resistance is unclear. While PZA resistance in MDR-TB, which is correlated with poor treatment outcome, ranges from 20-80% in some parts of the world, the frequency of PZA resistance in Russian MDR-TB strains is unknown. Therefore, the project will first analyze drug resistant clinical isolates of M. tb in Russian collection for polymorphisms in whiB7, tap, TA modules and RpsA and determine the frequency of PZA resistance in Russian MDR-TB strains. Second, the role of mutations in whiB7, tap, TA modules and rpsA in drug resistance and persistence/tolerance to antibiotics and stresses and survival in macrophages will be addressed. The proposed studies will fill in critical gaps in knowledge of drug resistance and persistence in M. tb. The outcome of this study will help to understand the mechanisms of drug resistance and persistence and provide useful information for design of persister drugs for shortening the TB treatment and improved treatment of drug-resistant TB.
The increasing drug resistant TB and mycobacterial persistence and HIV co-infection pose major threat for TB control. This project aims to address the role of several candidate genes in drug resistance and persistence in clinical isolates of M. tuberculosis in Russia where there is significant drug-resistant TB problem. The outcome of the study will help to understand mechanisms of drug resistance and persistence and provide useful information for design of new drugs and for improved treatment of drug-resistant TB.
|Feng, Jie; Weitner, Megan; Shi, Wanliang et al. (2016) Eradication of Biofilm-Like Microcolony Structures of Borrelia burgdorferi by Daunomycin and Daptomycin but not Mitomycin C in Combination with Doxycycline and Cefuroxime. Front Microbiol 7:62|
|Feng, Jie; Shi, Wanliang; Zhang, Shuo et al. (2016) A Drug Combination Screen Identifies Drugs Active against Amoxicillin-Induced Round Bodies of In Vitro Borrelia burgdorferi Persisters from an FDA Drug Library. Front Microbiol 7:743|
|Cui, Peng; Niu, Hongxia; Shi, Wanliang et al. (2016) Disruption of Membrane by Colistin Kills Uropathogenic E. coli Persisters and Enhances Killing of Other Antibiotics. Antimicrob Agents Chemother :|
|Zhang, Shuo; Chen, Jiazhen; Cui, Peng et al. (2016) Mycobacterium tuberculosis Mutations Associated with Reduced Susceptibility to Linezolid. Antimicrob Agents Chemother 60:2542-4|
|Xu, Tao; Han, Jian; Zhang, Jia et al. (2016) Absence of Protoheme IX Farnesyltransferase CtaB Causes Virulence Attenuation but Enhances Pigment Production and Persister Survival in MRSA. Front Microbiol 7:1625|
|Zhang, Shuo; Chen, Jiazhen; Cui, Peng et al. (2015) Identification of novel mutations associated with clofazimine resistance in Mycobacterium tuberculosis. J Antimicrob Chemother 70:2507-10|
|Maslov, Dmitry A; ZaÄchikova, Marina V; Chernousova, Larisa N et al. (2015) Resistance to pyrazinamide in Russian Mycobacterium tuberculosis isolates: pncA sequencing versus Bactec MGIT 960. Tuberculosis (Edinb) 95:608-12|
|Maslov, D A; Shur, K V; Bekker, O B et al. (2015) Draft Genome Sequences of Two Pyrazinamide-Resistant Clinical Isolates, Mycobacterium tuberculosis 13-4152 and 13-2459. Genome Announc 3:|
|Zhang, Y; Yew, W-W (2015) Mechanisms of drug resistance in Mycobacterium tuberculosis: update 2015. Int J Tuberc Lung Dis 19:1276-89|
|Shur, K V; Klimina, K M; Zakharevich, N V et al. (2015) Draft Genome Sequence of Mycobacterium tuberculosis Strain E186hv of Beijing B0/W Lineage with Reduced Virulence. Genome Announc 3:|
Showing the most recent 10 out of 14 publications